Publications by authors named "Elena I Kvasova"
Article Synopsis
- Azoximer bromide (AZB) was studied for its safety and efficacy in treating hospitalized COVID-19 patients, given its established benefits for upper respiratory infections in Russia.
- In the study, 81 patients received AZB in combination with standard care, showing clinical improvement with no deaths reported during hospitalization, but one patient required ongoing respiratory support after 28 days.
- Although AZB appeared to improve clinical outcomes and reduce hospitalization duration compared to a historical control group, more rigorous testing in a randomized, placebo-controlled trial is necessary to confirm its effectiveness.
Article Synopsis
- A study was conducted on 32 adults hospitalized with COVID-19, where they received the immune modulator azoximer bromide (AZB) alongside standard care, demonstrating a potential improvement in clinical status and a decrease in the severity of their condition.
- Patients were treated with AZB for a total of approximately ten injections over their hospital stay, averaging 20 days, and all were alive at discharge with improved oxygen saturation and no major side effects reported.
- While results indicated that AZB was safe and well tolerated, the study highlighted the need for further research through randomized, placebo-controlled trials to better determine its therapeutic effects in COVID-19 treatment.
